Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Naheema S Gordon, Laura A Baxter, Anshita Goel, Roland Arnold, Baljit Kaur, Wenyu Liu, Sarah J Pirrie, Syed Hussain, Richard Viney, Daniel Ford, Anjali Zarkar, Mary A Wood, Timur Mitin, Reid F Thompson, Nicholas D James, Douglas G Ward, Richard T Bryan

Research output: Contribution to journalArticlepeer-review

56 Downloads (Pure)
Original languageEnglish
Pages (from-to)32-34
Number of pages3
JournalBJU International
Volume129
Issue number1
Early online date7 Sep 2021
DOIs
Publication statusPublished - 1 Jan 2022

Bibliographical note

Funding Information:
The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

Funding Information:
Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board).

Funding Information:
The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

Funding Information:
The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

Keywords

  • Urology
  • Cetuximab/administration & dosage
  • Liquid Biopsy
  • Neoplasm Invasiveness
  • Humans
  • Treatment Outcome
  • Tumor Suppressor Protein p53/genetics
  • Neoplasm Recurrence, Local/genetics
  • Chemoradiotherapy
  • Sequence Analysis, DNA
  • Mitomycin/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Pilot Projects
  • Urinary Bladder Neoplasms/genetics
  • DNA, Neoplasm/analysis
  • Fluorouracil/administration & dosage
  • Muscle, Smooth/pathology
  • Mutation
  • Receptor, Fibroblast Growth Factor, Type 3/genetics
  • Clinical Trials, Phase I as Topic
  • Biomarkers, Tumor/urine
  • Clinical Trials, Phase II as Topic
  • Telomerase/genetics

Cite this